<SEC-DOCUMENT>0001486420-25-000007.txt : 20251114
<SEC-HEADER>0001486420-25-000007.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114170112
ACCESSION NUMBER:		0001486420-25-000007
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tvardi Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001346830
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87880
		FILM NUMBER:		251487931

	BUSINESS ADDRESS:	
		STREET 1:		3 SUGAR CREEK CTR. BLVD.
		STREET 2:		STE 525
		CITY:			SUGAR LAND
		STATE:			TX
		ZIP:			77478
		BUSINESS PHONE:		(713) 489-8654

	MAIL ADDRESS:	
		STREET 1:		3 SUGAR CREEK CTR. BLVD.
		STREET 2:		STE 525
		CITY:			SUGAR LAND
		STATE:			TX
		ZIP:			77478

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cara Therapeutics, Inc.
		DATE OF NAME CHANGE:	20100721

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cara Therapeutics Inc
		DATE OF NAME CHANGE:	20051213

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DePinho Ronald A
		CENTRAL INDEX KEY:			0001486420
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		AVEO PHARMACEUTICALS, INC.
		STREET 2:		75 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
		<previousAccessionNumber>0001415889-25-015080</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001486420</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>1</amendmentNo>
	      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001346830</issuerCik>        <issuerName>TVARDI THERAPEUTICS, INC.</issuerName>        <issuerCusip>140755208</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>3 Sugar Creek Ctr Blvd</com:street1>
          <com:street2>Suite 525</com:street2>          <com:city>Sugar Land</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>77478</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Ronald A. DePinho</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>626190.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>626190.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>626190.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>6.7</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>TVARDI THERAPEUTICS, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>3 Sugar Creek Ctr Blvd, Suite 525, Sugar Land, TX, 77478.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>Ronald A. DePinho</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>2929 Weslayan St.
Houston, TX 77027</principalBusinessOfficeOrResidenceAddress>        <citizenship>United States</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>Row 9 of the Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by the Reporting Person as of September 30, 2025 and is incorporated by reference.

The Reporting Person's ownership of the Issuer's securities consists of 626,190 shares of common stock directly held by the Reporting Person.</amountBeneficiallyOwned>    <classPercent>Row 11 of the Reporting Person's cover page to this Schedule 13G/A sets forth the percentage of the shares of common stock of the Issuer beneficially owned by the Reporting Person as of September 30, 2025 and is incorporated by reference. The percentage set forth in row 11 is based upon 9,379,332 shares of the Issuer's common stock outstanding as of September 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 13, 2025.</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>Row 5 of the Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by the Reporting Person as of September 30, 2025 and is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>Row 6 of the Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by the Reporting Person as of September 30, 2025 and is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>Row 7 of the Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by the Reporting Person as of September 30, 2025 and is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>Row 8 of the Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by the Reporting Person as of September 30, 2025 and is incorporated by reference.</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>


	    <signatureInformation>
      <reportingPersonName>Ronald A. DePinho</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Ronald A. DePinho</signature>
        <title>Ronald A. DePinho</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>

    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
